使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen, and welcome to Baxter International's third-quarter earnings conference call. Your lines will remain in a listen-only mode until the question-and-answer segment of today's call.
各位女士、先生,早安,歡迎參加百特國際(Baxter International)第三季財報電話會議。在今天電話會議的問答環節開始前,您的線路將維持僅收聽模式。
(Operator Instructions)
(接線員指示)
As a reminder, this call is being recorded by Baxter, and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.
提醒各位,本通話由百特錄音,並屬受著作權保護之資料。未經百特許可,不得錄音或轉播。如您有任何異議,請於此時中斷連線。
I would now like to turn the call over to Ms. Mary Kay Ladone, Corporate Vice President, Investor Relations at Baxter International. Ms. Ladone, you may begin.
現在我想把電話會議交給百特國際企業副總裁、投資人關係部的 Mary Kay Ladone 女士。Ladone 女士,您可以開始。
- Corporate VP, IR
- Corporate VP, IR
Thanks, John, and good morning, everyone, and welcome to our third-quarter 2012 earnings conference call. Joining me today are Bob Parkinson, CEO and Chairman of Baxter International; Bob Hombach, Chief Financial Officer; and Dr. Norbert Riedel, Chief Science and Innovation Officer.
謝謝你,John,各位早安,歡迎參加我們 2012 年第三季財報電話會議。今天與我一同出席的有:百特國際執行長暨董事長 Bob Parkinson、財務長 Bob Hombach,以及首席科學與創新長 Norbert Riedel 博士。
Before we get started, let me remind you that this presentation, including comments regarding our financial outlook, new product developments, and regulatory matters contain forward-looking statements that involve risks and uncertainties, and, of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially.
在開始之前,先提醒各位,本簡報(包含關於我們財務展望、新產品開發及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性;當然,我們的實際結果可能與目前預期有重大差異。有關可能導致實際結果與預期產生重大差異之因素,請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得更詳細資訊。
In addition, in today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning, and available on our website.
此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。今日所討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含於我們今早發布的財報新聞稿中,並可於我們網站取得。
Now I would like to turn the call over to Bob Parkinson.
現在我想把電話會議交給 Bob Parkinson。
- Chairman, CEO
- Chairman, CEO
Thanks, Mary Kay. Good morning, thanks for calling in. We are pleased today to announce our financial results for the third quarter, and also provide you with an update on Baxter's full-year 2012 outlook. As you saw in the press release that was issued earlier this morning, third-quarter sales after adjusting for FX increased 5%. EPS of $1.14 per diluted share increased 5% versus the prior year, and was in line with the guidance that we previously provided.
謝謝你,Mary Kay。各位早安,感謝撥冗來電。我們很高興在今天公布第三季財務結果,並向各位更新百特 2012 全年展望。如各位今早稍早發布的新聞稿所見,第三季銷售額在調整匯率(FX)影響後成長 5%。每股盈餘(EPS)為每股稀釋後 1.14 美元,較去年成長 5%,並符合我們先前提供的財測指引。
As we discussed with you all last week at the investor conference, we continue to focus on enhancing growth by optimizing our core business portfolio, advancing the Company's new product pipeline, pursuing and accelerating the pace of business development initiatives, and capitalizing on the opportunity to develop new business models, which includes public and private partnerships aimed at improving the quality of, and access to, care in both developed and emerging markets. Recent achievements reflect these priorities, and were highlighted in this morning's press release.
正如我們上週在投資人會議中與各位討論的,我們持續聚焦於透過最佳化核心業務組合、推進公司新產品研發管線、推動並加速業務開發計畫的步伐,以及把握發展新商業模式的機會來提升成長;其中包括公私部門合作夥伴關係,旨在改善已開發與新興市場的照護品質與可近性。近期成果反映了這些優先事項,並已在今早的新聞稿中重點說明。
As many of these topics were also covered thoroughly last week, I won't take too much time to review these in depth, but I would like to take a moment to highlight just a few key points. First, we continue to be very pleased with the success of our new ADVATE prophylaxis label in the US market, as evidenced by our strong sales performance in the quarter. And we remain committed to meeting patient needs by enhancing our plasma manufacturing footprint with both internal capacity expansions and external collaborations.
由於其中許多主題上週也已充分討論,我不會花太多時間深入回顧,但我想花點時間強調幾個重點。第一,我們對 ADVATE 在美國市場的新預防性治療(prophylaxis)適應症標示所取得的成功持續感到非常滿意,從本季強勁的銷售表現即可看出。我們也持續致力於滿足病患需求,透過內部產能擴充與外部合作,強化我們的血漿製造布局。
Second, we continue to successfully advance our pipeline. For example, during the quarter we submitted our regulatory file in the US for BAX 326, a recombinant factor IX protein, which, if approved, will be the only factor IX product indicated for prophylaxis treatment in the US, where most hemophilia B patients today are treated with an on-demand regimen.
第二,我們持續成功推進研發管線。例如,本季我們已在美國提交 BAX 326(重組第九凝血因子蛋白)的法規申請文件;若獲核准,該產品將成為美國唯一核准用於預防性治療的第九凝血因子產品,而目前多數血友病 B 病患仍採按需(on-demand)療法。
We also recently completed enrollment in our first home hemodialysis clinical trial, evaluating the performance and safety of our new device. This study was conducted at two centers in the US with 24 patients who collectively received more than 700 dialysis treatments. As you know, this data will support our European CE Marking in 2013.
我們也近期完成首項居家血液透析臨床試驗的收案,評估我們新裝置的效能與安全性。本研究在美國兩個中心進行,共納入 24 位病患,合計接受超過 700 次透析治療。如各位所知,這些數據將支持我們於 2013 年取得歐洲 CE 認證。
On the business development front, we entered into a collaboration with Onconova for European commercialization rights of rigosertib, a novel targeted anti-cancer compound. It is currently in a Phase III study for the treatment of MDS, a rare hematological malignancy, and is also in Phase II for an oral formulation for this indication. If approved, this will be an exciting addition to our portfolio, where we can leverage our legacy of treating critical diseases, our existing leadership position in hematology, and our sales channel. While hematology is our primary focus for this drug candidate, rigosertib is also in Phase II clinical trials for pancreatic cancer.
在業務開發方面,我們與 Onconova 達成合作,取得 rigosertib 於歐洲的商業化權利;rigosertib 是一種新型標靶抗癌化合物。目前該藥物正進行第三期臨床試驗,用於治療 MDS(骨髓增生異常症候群),這是一種罕見的血液惡性腫瘤;同時也針對此適應症的口服劑型進行第二期試驗。若獲核准,這將是我們產品組合令人振奮的新增項目;我們可運用在重大疾病治療的長期經驗、既有的血液學領導地位,以及銷售通路。雖然血液學是此候選藥物的主要聚焦領域,rigosertib 也正針對胰臟癌進行第二期臨床試驗。
In addition, under the terms of our agreement with Momenta Pharmaceuticals, we recently selected a third biosimilar for development, a monoclonal antibody for oncology designated as M511. This is in addition to the selection of M923 and M834 targeted for the treatment of autoimmune and other inflammatory disorders. As you know, Baxter and Momenta have the opportunity to develop up to six biosimilars through our partnership.
此外,依據我們與 Momenta Pharmaceuticals 的協議條款,我們近期選定第三個生物相似藥(biosimilar)進行開發,為一款腫瘤領域的單株抗體,代號 M511。這是在先前已選定 M923 與 M834(用於治療自體免疫及其他發炎性疾病)之外的新增項目。如各位所知,透過此合作夥伴關係,百特與 Momenta 最多可共同開發六項生物相似藥。
And finally, as we mentioned at our conference last week, the Brazilian government announced the award of an exclusive recombinant factor VIII hemophilia partnership in Brazil, the third largest hemophilia market in the world. While this agreement has not yet been finalized, we're working closely with the authorities there to enhance access to treatment, and provide recombinant therapies to patients, and we look forward to updating you on the significance of this award in the coming weeks.
最後,正如我們上週會議中提到的,巴西政府宣布授予在巴西(全球第三大血友病市場)一項重組第八凝血因子血友病合作案的獨家資格。雖然該協議尚未最終定案,我們正與當地主管機關密切合作,以提升治療可近性,並向病患提供重組療法;我們也期待在未來幾週向各位更新此項授予的重大意義。
In summary, our core portfolio remains strong, and we continue to benefit from our focus on life-saving therapies, which drives demand, moderates economic headwinds, and gives us a platform for geographic expansion. Our pipeline, as we discussed last week, is robust, addressing key high-potential areas of unmet medical need. We've accelerated the pace of business development. We remain disciplined to ensure that these opportunities align with our core strength, and we are committed to working with payers by establishing public and private partnerships, as we are very well-positioned to provide solutions to their increasing challenges. These are the vectors that will support our growth, and they will enable us to serve the interest of patients, and reward our shareholders, well into the future.
總結而言,我們的核心產品組合依然強勁;我們持續受惠於對救命療法的聚焦,這帶動需求、緩和經濟逆風,並為我們提供地理擴張的平台。如同上週所討論,我們的研發管線相當扎實,聚焦於多個高潛力且未被滿足的醫療需求領域。我們已加快業務開發的步伐。我們仍維持嚴謹紀律,確保這些機會與我們的核心優勢一致;同時我們也致力於透過建立公私部門合作夥伴關係與支付方合作,因為我們具備良好條件,能為其日益增加的挑戰提供解決方案。這些將是支撐我們成長的向量,並使我們在未來很長一段時間內,兼顧病患利益並回饋股東。
As always, I'd be happy to address any questions on these or other topics during the Q&A this morning. And with that, I would like to ask Bob to review our third-quarter financial results and guidance for the remainder of the year. Bob?
一如往常,我很樂意在今天上午的問答環節中,就這些或其他主題回答各位的問題。接下來,我想請 Bob 回顧我們第三季財務結果,以及今年剩餘期間的指引。Bob?
- Corporate VP and CFO
- Corporate VP and CFO
Thanks, Bob, and good morning, everyone. As Bob mentioned, earnings per diluted share in the third quarter excluding special items increased 5% to $1.14 per diluted share, which was at the high end of the guidance range we previously provided of $1.12 to $1.14 per diluted share. As mentioned in the press release, our GAAP results included an after-tax special charge of $45 million, or $0.08 per diluted share, related to the recently announced European licensing agreement with Onconova.
謝謝你,Bob,各位早安。如 Bob 所提到,第三季在排除特殊項目後,每股稀釋後盈餘較去年成長 5%,至每股稀釋後 1.14 美元,位於我們先前提供之每股稀釋後 1.12 至 1.14 美元指引區間的上緣。如新聞稿所述,我們的 GAAP 結果包含一筆稅後特殊費用 4,500 萬美元(或每股稀釋後 0.08 美元),與近期宣布的與 Onconova 之歐洲授權協議相關。
Now let me briefly walk you through the P&L by line item for the quarter, before turning to our financial outlook for the remainder of the year. Starting with sales, worldwide sales totaled approximately $3.5 billion in the third quarter, and were comparable to last year. On a constant-currency basis, revenues increased 5%, in line with our guidance, with notable double-digit sales growth of ADVATE and GAMMAGARD liquid in the US, and solid double-digit growth across many emerging markets. Collectively, this strength offset continued softness across mature markets in Western Europe. Third-quarter sales also included a benefit from the integration of the Synovis and Baxa acquisitions with combined sales of $65 million.
現在,在轉向我們對今年剩餘期間的財務展望之前,讓我先按季度損益表(P&L)的各項目,為各位做一個簡要說明。先從銷售額開始,第三季全球銷售額合計約35億美元,與去年同期相當。以固定匯率計,營收成長5%,符合我們的指引;其中,美國ADVATE與GAMMAGARD liquid的銷售呈現顯著的兩位數成長,且多個新興市場亦有穩健的兩位數成長。整體而言,這股強勁表現抵銷了西歐成熟市場持續疲弱的影響。第三季銷售亦包含整合Synovis與Baxa收購案所帶來的貢獻,兩者合計銷售額為6,500萬美元。
In terms of individual business performance, [global] BioScience sales to $1.5 billion were flat to last year, and excluding foreign currency, sales increased 5%. Within the product categories, recombinant sales increased 1% and totaled $555 million. On a constant-currency basis, sales increased 5%, as double-digit growth of 11% in the US was partially offset by the impact of the Australian tender. Excluding the impact of this tender, global recombinant sales advanced 8%. As Bob mentioned earlier, we continue to be very pleased with the strength of our US business, where we continue to realize benefits associated with the new expanded label of ADVATE, drive conversion from plasma-derived therapies and competitive offerings, and enhance penetration of prophylactic treatment.
就各事業部的個別表現而言,[全球] BioScience銷售額為15億美元,與去年持平;若排除外匯影響,銷售成長5%。在產品類別方面,重組產品(recombinant)銷售成長1%,合計5.55億美元。以固定匯率計,銷售成長5%;其中,美國11%的兩位數成長,部分被澳洲標案(tender)的影響所抵銷。若排除該標案影響,全球重組產品銷售以8%的幅度成長。如Bob先前提到的,我們對美國業務的強勁表現仍感到非常滿意;我們持續受惠於ADVATE新的擴大適應症標籤,推動從血漿衍生療法及競品的轉換,並提升預防性治療(prophylactic treatment)的滲透率。
Moving on to plasma proteins, sales in the quarter were $337 million, and were down 9%. On a constant-currency basis, sales declined 4%, as strong mid-teens growth in the US was more than offset by lower tender sales of FEIBA and plasma-derived factor VIII primarily in Brazil. Excluding this impact, plasma protein sales increased 9% on a constant-currency basis, with key products like FEIBA, albumin, and ARALAST registering double-digit gains.
接著看血漿蛋白(plasma proteins),本季銷售額為3.37億美元,下滑9%。以固定匯率計,銷售下滑4%;原因是美國中十位數(mid-teens)的強勁成長,仍不足以抵銷巴西FEIBA與血漿衍生第VIII因子(factor VIII)標案銷售下滑的影響。若排除該影響,血漿蛋白銷售以固定匯率計成長9%,FEIBA、白蛋白(albumin)與ARALAST等主要產品均呈現兩位數成長。
In antibody therapy, sales of $404 million increased 6%. Excluding currency, sales accelerated 9%, driven by unit volume growth in mid-single digits and positive price benefits resulting from favorable shifts in our geographic mix as we optimize our global supply in light of the LA facility shutdown, which is currently underway. Also, as I mentioned earlier, we are very pleased with our performance in the US, where antibody therapy sales advanced 12%, driven by robust demand for GAMMAGARD liquid as we continue to promote awareness and diagnosis of primary immune deficiency, and drive enhanced penetration of subcu therapy given are favorable tolerability profile and low infusion-site reaction rate. As a reminder, global sales related to the Octapharma absence in the third quarter of 2011 were approximately $20 million. After adjusting for this, antibody therapy revenues advanced more than 15%.
在抗體治療(antibody therapy)方面,銷售額4.04億美元,成長6%。若排除匯率影響,銷售加速成長9%,主要由中個位數的出貨量成長,以及在洛杉磯(LA)廠區停工(目前正在進行)之際,我們為優化全球供應而帶來的地理組合有利變化所產生的正向價格效益所驅動。此外,如我先前提到的,我們對美國市場的表現也非常滿意;抗體治療銷售成長12%,主要受GAMMAGARD liquid需求強勁帶動,我們持續提升對原發性免疫缺陷(primary immune deficiency)的認知與診斷,並在其良好耐受性與低注射部位反應率的支持下,推動皮下(subcu)治療的滲透率提升。提醒各位,2011年第三季因Octapharma缺席所帶來的相關全球銷售約為2,000萬美元。在此調整後,抗體治療營收成長超過15%。
In the third quarter, sales in regenerative medicine advanced 15% to $165 million. On a constant-currency basis, sales rose 20%, driven by growth of TISSEEL and FLOSEAL, and the incremental benefit from the Synovis acquisition of approximately $20 million.
第三季,再生醫學(regenerative medicine)銷售成長15%至1.65億美元。以固定匯率計,銷售成長20%,主要由TISSEEL與FLOSEAL的成長,以及Synovis收購案帶來約2,000萬美元的增量貢獻所驅動。
Finally, revenues in the Other category totaled $61 million in the quarter, and declined 13%. Excluding foreign currency, sales were flat as lower third-party plasma sales were offset by growth of vaccines, including the ongoing revenues related to our influenza collaboration in Japan with Takeda. In Medical Products, global sales in the third quarter of approximately $2 billion were comparable to last year. Sales increased 4% on a constant-currency basis.
最後,Other類別本季營收合計6,100萬美元,下滑13%。若排除外匯影響,銷售持平,因第三方血漿銷售下滑被疫苗成長所抵銷,其中包括我們與武田(Takeda)在日本的流感合作所帶來的持續性收入。在醫療產品(Medical Products)方面,第三季全球銷售約20億美元,與去年同期相當。以固定匯率計,銷售成長4%。
Within the product categories, renal sales totaled $629 million, and declined 3%. Excluding currency, sales increased 2%, as global PD growth, supported by solid patient gains, was offset by lower HD revenues. Sales in the global injectables category of $509 million increased 3%, and on a constant-currency basis, sales increased 7%. Performance continues to be driven by significant growth in our international pharma partnering and compounding businesses, growth of certain injectable therapeutics like cyclophosphamide, a generic oncology drug, and the incremental benefit of the Baxa acquisition with sales of approximately $10 million. IV therapy sales advanced 6% to $479 million. Excluding currency, sales increased 12%, driven by higher demand for IV and nutritional therapies, and sales of $35 million related to the Baxa acquisition.
在產品類別中,腎臟(renal)業務銷售合計6.29億美元,下滑3%。若排除匯率影響,銷售成長2%;全球腹膜透析(PD)在穩健的病患增加支持下成長,但被血液透析(HD)營收下滑所抵銷。全球注射劑(injectables)類別銷售5.09億美元,成長3%;以固定匯率計,銷售成長7%。表現持續由國際藥廠合作夥伴與調劑(compounding)業務的顯著成長、部分注射型治療藥物(如環磷醯胺cyclophosphamide,此為學名腫瘤用藥)的成長,以及Baxa收購案帶來約1,000萬美元銷售的增量貢獻所驅動。靜脈(IV)治療銷售成長6%至4.79億美元。若排除匯率影響,銷售成長12%,主要由對靜脈與營養治療需求提升,以及與Baxa收購案相關的3,500萬美元銷售所帶動。
Infusion systems sales totaled $186 million, and were lower than the prior year by 16%. On a constant-currency basis, sales declined 14% due to lower access set revenues, and the difficult comparison presented by the completed transition to the Spectrum pump in the US. Finally, our anesthesia franchise posted sales of $135 million, reflecting an increase of 5%. Excluding currency, sales advanced 9%, driven by solid gains in sevoflurane and Suprane, particularly in international markets.
輸注系統(infusion systems)銷售合計1.86億美元,較去年同期下滑16%。以固定匯率計,銷售下滑14%,原因為通路組件(access set)營收較低,以及美國已完成轉換至Spectrum幫浦所造成的比較基期不利。最後,我們的麻醉(anesthesia)產品線銷售為1.35億美元,成長5%。若排除匯率影響,銷售成長9%,主要由sevoflurane與Suprane的穩健成長所帶動,尤其是在國際市場。
Turning to the rest of the P&L, gross margin for the Company improved to 52.1%, reflecting sequential expansion and an improvement of 120 basis points versus the prior year. This was a result of underlying operational expansion driven primarily by positive mix and a benefit from foreign currency. These factors more than offset a number of headwinds including pension, amortization of intangible assets related to recent business development activities, and austerity measures.
接著看損益表(P&L)的其餘項目,公司毛利率提升至52.1%,反映毛利率連續季度擴張,且較去年同期改善120個基點。這主要來自於營運面的結構性擴張,主要由有利的產品組合與外匯帶來的助益所驅動。上述因素已足以抵銷多項逆風,包括退休金、近期業務開發活動相關之無形資產攤銷,以及撙節措施。
SG&A totaled $743 million, and increased 5%, with 3 points of growth associated with the integration of recent acquisitions. We also continue to invest in promotional and marketing initiatives (inaudible) and in international markets to enhance our global presence. These items, along with incremental pension expense, more than offset the benefit from foreign currency, aggressive management of discretionary spending, and operational efficiencies derived from our PowerUp re-engineering initiatives.
銷售、一般及行政費用(SG&A)合計7.43億美元,成長5%,其中有3個百分點的成長與近期收購案的整合相關。我們也持續投資於推廣與行銷計畫(聽不清)以及國際市場,以強化我們的全球布局。這些項目加上退休金費用的增加,已超過外匯帶來的效益、對可自由裁量支出的積極管理,以及我們PowerUp流程再造計畫所帶來的營運效率提升。
As expected, R&D spending moderated in the third quarter, and totaled $240 million. Growth on a constant-currency basis was in high-single digits as we continue to advance a number of programs, including those in our leading hemophilia franchise, the Alzheimer's programs, and Phase III adult stem cell trial.
如預期,第三季研發(R&D)支出趨於緩和,合計2.40億美元。以固定匯率計,成長為高個位數(high-single digits),因我們持續推進多項計畫,包括我們領先的血友病產品線、阿茲海默症計畫,以及第三期成人幹細胞試驗。
The operating margin in the quarter was 23.8%, an improvement of almost 200 basis points sequentially, and slightly higher than the margin in the third quarter of last year. Interest expense was $25 million, and compared to $14 million last year. This increase is due to incremental expense associated with recent debt issuances and lower interest income.
本季營業利益率為23.8%,較前一季提升近200個基點,且略高於去年第三季的水準。利息費用為2,500萬美元,去年同期為1,400萬美元。此增幅主要由近期發債所帶來的增量費用,以及利息收入較低所致。
Other income totaled $14 million in the quarter compared to an expense of $6 million last year, primarily a result of favorable foreign exchange impact on balance sheet positions, which totaled approximately $10 million. The tax rate was 23% for the quarter, higher than projected due to earnings mix, which brings the year-to-date rate to 22%. And finally, as previously mentioned, adjusted EPS was $1.14 per diluted share, an increase of 5%.
本季其他收益合計1,400萬美元,相較去年同期為600萬美元的費用,主要是因外匯對資產負債表部位的有利影響,合計約1,000萬美元。本季稅率為23%,因獲利組合影響而高於預期,使得年初至今稅率為22%。最後,如先前所提,調整後每股盈餘(EPS)為每股稀釋後1.14美元,成長5%。
Turning to cash flow, cash flow from operations in the quarter totaled $747 million, and on a year-to-date basis cash flow from operations of $2.2 billion advanced 12%. Capital expenditures of $259 million in the third quarter compares to spending of $235 million in 2011. DSO ended the quarter at 57 days compared to a DSO of 54.5 days last year. This increase can be attributed to growth in both the US and international receivables. Inventory turns of 2.3 are lower than turns of 2.5 last year due to the impact of recent acquisitions, and increased inventory levels to support late-stage clinical trials and growing demand. Lastly, on a year-to-date basis, we repurchased 19 million shares for $1.9 billion, or on a net basis, approximately 13 million shares for $772 million, and we remain on track to achieve our full-year objective of net share repurchases totaling approximately $1 billion.
談到現金流,本季營運活動現金流合計為7.47億美元;以年初至今計,營運活動現金流22億美元成長12%。第三季資本支出為2.59億美元,對比2011年的支出2.35億美元。本季末DSO為57天,去年為54.5天。此一增加可歸因於美國及國際應收帳款的成長。存貨周轉率2.3次,低於去年的2.5次,主要因近期併購的影響,以及為支援後期臨床試驗與日益成長的需求而提高存貨水位。最後,以年初至今計,我們以19億美元回購1,900萬股;或以淨額計,約以7.72億美元回購約1,300萬股;我們仍按計畫達成全年目標:淨回購股份總額約10億美元。
Finally, let me conclude my comments this morning by providing our financial outlook for the third-quarter and full-year 2012. First, for the full year, we now expect earnings of $4.51 to $4.54 per diluted share. By line item of the P&L, and starting with sales, we continue to project full-year sales growth excluding foreign currency of 4% to 5%. Given our current outlook for foreign exchange rates, we expect currency to have a negative impact on the top line of approximately 3 percentage points. Therefore, we expect reported sales growth, which includes the impact of foreign currency, to be approximately 2%. We now expect full-year gross margin rate for the Company to expand modestly versus last year's rate of 51.4%. We expect SG&A to grow in mid-single digits, and now we expect R&D to grow in high-single digits.
最後,讓我在今天上午的發言結尾,提供我們對2012年第三季與全年之財務展望。首先,就全年而言,我們目前預期稀釋後每股盈餘為4.51至4.54美元。就損益表各項目而言,先從銷售額開始,我們仍預估在排除外幣影響後,全年銷售成長為4%至5%。依據我們目前對匯率的展望,我們預期匯率將對營收(top line)造成約3個百分點的負面影響。因此,我們預期包含外幣影響的報告銷售成長約為2%。我們目前預期公司全年毛利率將較去年的51.4%小幅擴張。我們預期SG&A將以中個位數成長,且目前預期R&D將以高個位數成長。
We now expect interest expense to total approximately $90 million, and Other, including non-controlling interest, to be an income item of approximately $50 million driven primarily by a benefit of currency and the benefit in the first half related to minority interest income. Given the year-to-date changes in our earnings mix, we now expect a tax rate of approximately 22%, with a full-year average share count of approximately 555 million shares, which assumes $1 billion in net share repurchases. From a cash flow perspective, we plan to generate cash flow from operations of more than $3 billion.
我們目前預期利息費用合計約9,000萬美元;其他項目(含非控股權益)預期為約5,000萬美元的收益項目,主要由匯兌利益以及上半年與少數股權收益相關的利益所帶動。鑑於年初至今我們獲利組合的變化,我們目前預期稅率約為22%,全年平均流通股數約為5.55億股,該假設包含10億美元的淨股份回購。就現金流角度而言,我們計畫產生超過30億美元的營運活動現金流。
Now to expand on the full-year sales assumptions for each of the businesses. First, on a constant-currency basis, we continue to expect Medical Products sales to grow in the mid-single digits. This includes IV therapy sales growth of approximately 10%; anesthesia sales growth in mid-single digits; global injectable sales growth in mid-single digits; lower infusion systems sales, which are expected to decline approximately 5% to 10%; and lastly, renal sales are expected to grow in low-single digits.
接著進一步說明各事業的全年銷售假設。首先,以固定匯率基礎(constant-currency)計,我們仍預期醫療產品(Medical Products)銷售將以中個位數成長。其中包括:IV治療銷售成長約10%;麻醉產品銷售以中個位數成長;全球注射劑銷售以中個位數成長;輸注系統銷售較低,預期下滑約5%至10%;最後,腎臟相關銷售預期以低個位數成長。
For BioScience, we continue to project sales growth excluding foreign currency in the mid-single digits. Our outlook includes recombinant sales growth in low- to mid-single digits reflecting the strong year-to-date growth in the US; plasma protein sales growth in low-single digits; antibody therapy sales growth in mid-single digits; regenerative medicine sales growth approaching 20%; and finally, we expect the Other category to grow approximately 5%, which includes an anticipated milestone payment in the fourth quarter related to our US influenza vaccine program.
就BioScience而言,我們仍預估在排除外幣影響後,銷售成長為中個位數。我們的展望包括:重組產品(recombinant)銷售以低至中個位數成長,反映美國年初至今的強勁成長;血漿蛋白(plasma protein)銷售以低個位數成長;抗體治療(antibody therapy)銷售以中個位數成長;再生醫學(regenerative medicine)銷售成長接近20%;最後,我們預期其他(Other)類別成長約5%,其中包含與我們美國流感疫苗計畫相關、預計於第四季取得的一筆里程碑款項。
As mentioned in our press release, for the fourth quarter we expect earnings per diluted share of $1.24 to $1.27, and sales growth excluding the impact of foreign currency of 5% to 6%. Based on our outlook for foreign exchange rates, we expect currency to impact sales by approximately 2 percentage points. Therefore, we expect reported sales growth of approximately 3% to 4%.
如同我們新聞稿所述,我們預期第四季稀釋後每股盈餘為1.24至1.27美元,且在排除外幣影響後的銷售成長為5%至6%。依據我們對匯率的展望,我們預期匯率將使銷售受到約2個百分點的影響。因此,我們預期報告銷售成長約為3%至4%。
Thanks, and now we'll open up the call for Q&A.
謝謝,接下來我們將開放問答。
Operator
Operator
Thank you.
謝謝。
(Operator Instructions)
(接線員指示)
I would like to remind participants this call is being recorded and a digital replay will be available on the Baxter International website for 30 days at www.baxter.com. Our first question comes from Larry Keusch of Raymond James. Please go ahead with your question.
提醒各位與會者,本次電話會議將被錄音,並將於Baxter International網站提供為期30天的數位重播,網址為www.baxter.com。我們的第一個問題來自Raymond James的Larry Keusch。請提出您的問題。
- Analyst
- Analyst
Great. Thank you, good morning, everyone.
很好。謝謝,各位早安。
- Chairman, CEO
- Chairman, CEO
Good morning.
早安。
- Analyst
- Analyst
Bob, I know that it is obviously early here and you haven't given specific guidance for 2013, but would you mind just sharing some thoughts on just how you're thinking about the environment as we sort of head into next year?
Bob,我知道現在顯然還早,而且你們尚未提供2013年的具體指引,但你介意分享一下,當我們邁向明年時,你們對整體環境的看法與思考方向嗎?
- Chairman, CEO
- Chairman, CEO
Sure, Larry, I will make some comments and then maybe turn it over to Bob Hombach. Hopefully you all got a good context of this last week, and you're right, we're not going to get into the specifics for 2013, this morning. Clearly, we anticipate that the environment is going to continue to be very challenging, that is one of the assumptions that Bob Hombach had on one of his early slides in the presentation last week. Going to continue to be very demanding.
當然可以,Larry。我先做一些評論,然後也許再交給Bob Hombach補充。希望大家上週已經獲得很好的背景脈絡;你說得沒錯,我們今天早上不會深入談2013年的細節。很明顯地,我們預期整體環境將持續非常具挑戰性;這也是Bob Hombach上週簡報中某張前段投影片所採用的假設之一。未來仍將非常嚴峻。
Obviously, as we move into '13, we do have a couple of issues that we are going to need to deal with which are unique to next year. The device tax, which you are all familiar with, which is not insignificant in its impact. We are going to continue to be constrained on plasma capacity through the year in 2014, of course, with the Sanguin deal that we recently announced. It will put us in a much better position. Interest rates remain very low, so in terms of pension exposure and so on, that might be a bit of a headwind as well. But you got a sense of the long-term guidance last week that Bob provided. The environment is going to continue to be challenging, but as I commented in my prepared comments this morning, the underlying drivers of our business continue to be very solid.
顯然,當我們進入2013年時,確實有幾個需要處理、且為明年所特有的議題。醫療器材稅(device tax),各位都很熟悉,其影響不容小覷。當然,我們在2014年之前的一整年仍將受限於血漿產能;不過,隨著我們近期宣布的Sanguin交易,將使我們處於更有利的位置。利率仍然非常低,因此就退休金曝險等面向而言,這也可能帶來一些逆風。不過,各位上週已從Bob提供的長期指引中有所感受。環境將持續具挑戰性,但如同我今天上午在事先準備的發言中所說,我們業務的基本驅動因素仍然非常穩健。
And we're making, I think, great progress on a lot of fronts. So I'll stop there. I don't know, Bob, if you want to add anything to that? I probably covered most of the things that you would comment on, but there may be -- you or Mary Kay?
而且我認為我們在許多面向都取得了很大的進展。我就先說到這裡。Bob,不知道你是否想補充?我大概涵蓋了你會評論的大部分事項,但也許——你或Mary Kay?
- Corporate VP and CFO
- Corporate VP and CFO
Yes, I would just reiterate a lot of what Bob said, but also just highlight a few of the key factors that we talked about last week. Certainly, our expectation around the environment as it relates to Western Europe in particular is that we don't see any significant improvement. We started out this year with an expectation that Western Europe is going to be, call it flattish in 2012, and that held up pretty well through the first half of the year, but we certainly saw incremental softness in the third quarter and now expect for the full year that Western Europe from a top line perspective will be down slightly. And as we go into next year that is something we will definitely be factoring into our thinking.
是的,我想重申Bob所說的許多內容,同時也強調幾個我們上週談到的關鍵因素。當然,就環境而言,特別是與西歐相關的部分,我們不認為會有任何顯著改善。我們在今年一開始的預期是:西歐在2012年大致持平;上半年這個判斷維持得相當不錯,但我們確實在第三季看到額外的疲弱,因此目前預期就全年而言,西歐在營收(top line)方面將小幅下滑。而當我們進入明年時,這將是我們思考中一定會納入的因素。
But the dynamics of the business as we talked about yesterday, we still see opportunities to drive incremental leverage whether it's in gross margin or in SG&A over time, modest, but incremental, through some of our re-engineering initiatives due to the positive business mix that we expect to continue to see in the business, even withstanding some of the headwinds that Bob mentioned that we've already talked about for 2013. And putting that all together is why we directionally indicated last week that our long-range outlook is 7% to 9% for EPS growth but that in 2013 would be at the low end of that.
但就像我們昨天談到的業務動態一樣,我們仍然看到有機會隨時間推動額外的槓桿,不論是在毛利率或在SG&A方面;幅度不大,但可逐步提升。這主要來自我們部分再工程計畫,以及我們預期業務中將持續出現的正向產品組合,即使要承受Bob提到、我們也已經談過的2013年一些逆風因素。把這些因素綜合起來,就是為什麼我們上週在方向上指出,我們的長期展望是EPS成長7%到9%,但2013年會落在該區間的低端。
- Analyst
- Analyst
Okay, perfect. And just one other quick one. You mentioned infusion and I understand the comps. Can you just talk a little bit about the dynamics in the set business and the ability to now start to perhaps raise price on pumps now that the Colleague recall has now been completed?
好的,完美。另外再快速問一個。你提到輸注(infusion),我也理解可比基期(comps)。你能否稍微談談輸注器材(set)業務的動態,以及在Colleague召回現在已經完成之後,是否有能力開始、或許提高幫浦(pump)價格?
- Chairman, CEO
- Chairman, CEO
Yes, this is Bob Parkinson, Larry. We're not going to comment specifically on pricing strategies for reasons I am sure you understand. We completed the Colleague activity in terms of all of the pumps out of the market, so we continue to manage through what I'll call kind of stabilizing time in the market. We had, as Bob mentioned, some tough comps because a year ago was when we were pretty significantly expanding our SIGMA placements. So I think the set business, the access set business, is starting to settle out. I would tell you I don't see a robust turnaround in that at all in the coming couple of quarters. I think we're still going to go through what I'll just, as I characterize kind of settling out period here.
是的,我是Bob Parkinson,Larry。基於一些原因(我相信你能理解),我們不會具體評論定價策略。就把所有幫浦退出市場而言,我們已完成Colleague相關作業,因此我們仍在管理我所稱的市場「穩定期」。我們確實有一些艱難的可比基期,因為一年前正是我們相當大幅擴大SIGMA裝機(placements)的時候。所以我認為set業務、也就是輸注管路(access set)業務,正在開始趨於穩定。我會說,在接下來幾個季度我完全不認為那會出現強勁反轉。我想我們仍會經歷一段我所形容的「逐步穩定」期間。
- Corporate VP, IR
- Corporate VP, IR
Yes, I would agree, Larry, we are not expecting the set revenue growth to change dramatically for the next several quarters due to the comps, as now we've replaced all the Colleagues with the Spectrum but we are seeing now the share loss that we've experienced impact our disposable set sales.
是的,Larry,我同意。我們不預期由於可比基期的因素,set營收成長在接下來幾個季度會有劇烈變化;因為我們現在已用Spectrum替換了所有Colleague,但我們也看到先前經歷的市占流失正在影響我們的一次性(disposable)set銷售。
- Analyst
- Analyst
Got it. Okay. Thanks very much.
了解。好的。非常感謝。
- Corporate VP, IR
- Corporate VP, IR
Yes. Next question, Sean.
是的。下一個問題,Sean。
Operator
Operator
Mike Weinstein of JPMorgan is on the line with a question. Please go ahead with your question.
摩根大通(JPMorgan)的Mike Weinstein在線上有問題。請提出您的問題。
(Operator Instructions)
(接線員指示)
Mike, your line is open, please go ahead. Our next question --
Mike,您的線路已開通,請開始。我們的下一個問題——
- Chairman, CEO
- Chairman, CEO
We will go ahead and move on. Mike can get back in the queue if he is on.
我們先繼續往下進行。如果Mike在線上,他可以再回到提問隊列。
Operator
Operator
Sure, he can press star 1 to jump back in the queue. Our next question comes from Rajeev Jashnani with UBS. Please go ahead with your question.
好的,他可以按星號1回到提問隊列。我們的下一個問題來自UBS的Rajeev Jashnani。請提出您的問題。
- Analyst
- Analyst
Hi, can you hear me.
嗨,你們聽得到我嗎?
- Chairman, CEO
- Chairman, CEO
Hi, Rajeev, yes we can, go ahead, please.
嗨,Rajeev,可以的,請說。
- Analyst
- Analyst
Good morning.
早安。
- Chairman, CEO
- Chairman, CEO
Good morning.
早安。
- Analyst
- Analyst
Just on recombinants, I think, obviously, the US market looks like it continues to be pretty strong here and I know you had talked about some stocking in the first half and I was just wondering if you could give us some perspective on whether the growth you're seeing now is really representative of what you think is the underlying growth rate in the market? And then maybe also, if you could, any level of quantification on where you think penetration is in terms of adult prophylaxis now versus, say, one year ago?
關於重組產品(recombinants),我想很明顯美國市場看起來仍相當強勁。我知道你們談到上半年有一些備貨(stocking),我想請你們提供一些觀點:你們現在看到的成長,是否真的代表你們認為市場的基本(underlying)成長率?另外,如果可以的話,能否稍微量化一下:就成人預防性治療(adult prophylaxis)而言,你們認為目前的滲透率大概在哪裡,相較於一年前?
- Chairman, CEO
- Chairman, CEO
Okay. Bob, Mary Kay, you guys want to --?
好的。Bob、Mary Kay,你們要——?
- Corporate VP and CFO
- Corporate VP and CFO
Yes, Rajeev, we certainly have seen strong results here in the first three quarters. As we talked about on the first half of the year, with the new ADVATE [prophy] label we did expect that some of that was stocking. As we go into the fourth quarter, our expectation would be to grow more in line with the market, maybe slightly faster, but certainly not the double-digits that we've been posting here. I would say, though, that we are in the early days of really benefiting from the PK dosing, the every three-day dosing opportunity that we have within the US.
是的,Rajeev,我們在前三個季度確實看到強勁的結果。如同我們在上半年談到的,隨著新的ADVATE(預防用藥)標籤(label),我們確實預期其中一部分是備貨所致。進入第四季後,我們的預期是成長會更接近市場水準,可能略快一些,但肯定不會是我們目前呈現的兩位數成長。不過我會說,我們才剛開始真正受益於PK劑量調整(PK dosing),也就是在美國每三天給藥一次(every three-day dosing)的機會。
As Ludwig Hantson mentioned last week with the August approval for the 4000 IU for ADVATE that really puts us in a great position to go out and work with patients and treaters to convert them to every three-day dosing because that allows them to use of single vial to do the increased dosing required to do every three days. So we're very early days in that, as well. We are very excited about the opportunity, but I would expect in the fourth quarter we would see a moderation here from the growth rate that we've seen in the first three quarters but still strong.
正如Ludwig Hantson上週提到的,ADVATE在8月獲准4000 IU規格,這讓我們處於非常有利的位置,可以與病患及治療者合作,推動他們轉換到每三天給藥一次,因為這使他們能用單一瓶(single vial)來完成每三天給藥所需的較高劑量。所以這方面我們也仍在非常早期的階段。我們對這個機會非常興奮,但我預期第四季的成長率會較前三季有所降溫,但仍會維持強勁。
- Corporate VP, IR
- Corporate VP, IR
Yes, Rajeev, I would add, I don't have a year over year perspective I can give you an adult prophylaxis, but today our projection is that about 15% of all the patients that are in the US, that 15% our adult on [prophy.] So there's a large opportunity to continue to convert, especially in light of our ADVATE label.
是的,Rajeev,我補充一下:我沒有可以提供的成人預防性治療年對年比較數據,但我們目前的推估是,在美國所有病患中,大約15%是成人且採用(預防性治療)。因此仍有很大的轉換空間,特別是考量到我們的ADVATE標籤。
- Analyst
- Analyst
Yes. And I did have one follow-up on IVIG, I think you mentioned volume growth was up mid-singles and I was wondering if you could comment on whether that sort of a sustainable level of volume growth that we can expect over the next few quarters until the capacity constraints ease a little bit? And, I guess, secondly, just on the geographic transition, how much more of that is left given where the geographic mix currently stands? Thanks.
是的。我還有一個關於IVIG的追問:我想你提到量的成長是中個位數(mid-singles),我想請問在產能限制稍微緩解之前,未來幾個季度我們是否可以預期這樣的量成長水準是可持續的?另外,關於地理區域的轉移(geographic transition),以目前的地理組合來看,還剩下多少需要完成?謝謝。
- Chairman, CEO
- Chairman, CEO
Yes, I would say we're pretty far along with the geographic shift that we are looking to accomplish here, really started in the second quarter and I think accelerate to a level in the third quarter we will be at on a run rate basis going forward here. As it relates to volume, I do believe that mid-single-digit unit volume growth is a sustainable level for us as we go forward. As we mentioned last week, we are now in the process of working through the modest refurbishments that we need to do to the older facility in LA. We've built up enough paste in advance of that to support a mid-single-digit unit volume as we go forward. As we mentioned also, we recently received approval in the third quarter in Rieti for the capacity expansion we have coming online there, so that will be ramping up.
是的,我會說我們在要達成的地理區域轉移方面已經相當接近完成;這其實從第二季開始,並在第三季加速到一個水準,我們往後將以此作為運行率(run rate)。至於量的部分,我確實認為中個位數的單位量(unit volume)成長,對我們而言在未來是可持續的水準。如同我們上週提到的,我們現在正在進行洛杉磯(LA)舊廠所需的一些小幅整修(refurbishments)。我們已事先建立了足夠的血漿中間體(paste)庫存,以支撐未來中個位數的單位量。另外如同我們也提到的,我們在第三季近期已取得Rieti的核准,讓那裡的產能擴充可以上線,因此將逐步爬坡(ramping up)。
We continue to work to expand capacity utilization in new LA. So there's a number of factors here that will play into that but we do think as we go into 2013 that single-digit volume growth is a sustainable level for us. And as we get into 2014, certainly with Rieti being more ramped up, with new LA reaching hopefully full potential, with old LA being back online, and the Sanguin deal then our volume situation becomes significantly better in 2014.
我們也持續努力提升新LA廠的產能利用率。因此這裡有多項因素會影響,但我們確實認為進入2013年後,個位數的量成長對我們而言是可持續的水準。而到了2014年,隨著Rieti更充分爬坡、新LA廠希望達到滿載潛力、舊LA廠恢復上線,以及Sanguin交易的影響,我們在量的供應情況於2014年將顯著改善。
- Analyst
- Analyst
Thanks a lot.
非常感謝。
Operator
Operator
Our next question, David Roman of Goldman Sachs is on the line with our question. Please go ahead with your question.
我們的下一個問題,Goldman Sachs 的 David Roman 在線上提問。請提出您的問題。
- Analyst
- Analyst
Good morning, everyone.
各位早安。
- Chairman, CEO
- Chairman, CEO
Hi, David.
嗨,David。
- Analyst
- Analyst
Good morning, Bob. Was hoping on the O US plasma protein trends, is there any connection between either the country destocking ahead of picking up recombinants? Are the two at all connected?
早安,Bob。我想就美國血漿蛋白的趨勢請教,是否與某些國家在重組產品回升之前先行去庫存有任何關聯?這兩者之間有任何連結嗎?
- Corporate VP and CFO
- Corporate VP and CFO
No, David, if you are referring to Brazil, no, the answer is they are disconnected. I think I mentioned actually in the third quarter call, that we were likely going to have some timing differences between tender shipments between the third and fourth quarter and that certainly has played out even a bit more than we expected. So the fourth quarter timing around tenders is not related to anything with that. Now there is the opportunity, but to the extent that we conclude an agreement, to have some participation in recombinant factor VIII in Brazil in the fourth quarter, and part of our guidance range.
不,David,如果你指的是巴西,不,答案是兩者沒有關聯。我想我其實在第三季電話會議中提到過,我們很可能會在第三季與第四季之間的標案出貨時點上出現一些時間差,而這確實發生了,甚至比我們預期的還要多一些。所以第四季標案的時點與那方面沒有任何關係。不過確實存在機會,但前提是我們達成協議,能在第四季於巴西參與部分重組第八凝血因子,這也包含在我們的指引區間內。
I would characterize the year end this year as a bit more uncertain than we would normally see, whether it's mature markets like Western Europe where governments are under significant budget constraints and whether there's activity slowdown utilization in the fourth quarter or not is something that we're keeping a close eye on, but also just volatility around emerging markets and year end shipments. Those are some of the reasons why we've gone with the $0.03 range in the fourth quarter trying to accommodate some of that potential variability, but not related to anything in terms of the Brazil per se.
我會把今年年底的情況形容為比我們通常看到的更不確定;不論是像西歐這樣的成熟市場,政府面臨相當大的預算限制,第四季是否會出現活動放緩、使用量下降,我們都在密切關注;同時也有新興市場與年底出貨的波動。這些都是我們在第四季採用 0.03 美元區間的部分原因,試圖容納一些潛在的變動性,但這與巴西本身並無關聯。
- Corporate VP, IR
- Corporate VP, IR
And, David, I would add the majority of the tender timing is really related to FEIBA and not PD factor VIII, although that was a piece of it. And the total impact in the quarter on sales was about $45 million.
另外,David,我補充一下:大部分標案時點其實與 FEIBA 有關,而不是血漿來源的第八凝血因子(PD factor VIII),雖然那也是其中一部分。而本季對銷售的總影響約為 4,500 萬美元。
- Analyst
- Analyst
Okay. That's helpful. And then maybe for Bob Parkinson, it's sort of a strategic question, as you look at this quarter's growth rate, 8% in the United States, it's probably one of the better growth rates we've seen across all of healthcare in the US. And then Bob just mentioned pressures in Europe and I know you think about emerging markets. When you look at your investment priorities, how do you sort of tier the emerging markets versus the US versus Western Europe? Is it fair to say Western Europe is being de-emphasized for those other two regions? How do you sort of think about your --
好的。這很有幫助。接著可能想問 Bob Parkinson,一個偏策略性的問題:就本季在美國 8% 的成長率來看,這大概是我們在美國整體醫療保健領域看到較好的成長率之一。然後 Bob 剛提到歐洲的壓力,我也知道你們會考量新興市場。當你們看投資優先順序時,會如何在新興市場、美國與西歐之間分層排序?是否可以說西歐相較於另外兩個地區被弱化了?你們如何看待你們的——
- Chairman, CEO
- Chairman, CEO
No, not at all. Despite the challenging environment in Western Europe, the reality is I think we have opportunities to do better. And we are still making selective investments where there are, what I'll just call, promotional pressure points throughout all of our businesses. That's necessary to do. The strength in the US both in the quarter and year-to-date has been encouraging, not sure how sustainable it is quite at that level going forward, as Jean-Luc Batel featured last week at the investor conference.
不,完全不是。儘管西歐環境具挑戰性,現實是我認為我們仍有機會做得更好。而且我們仍在有選擇地投資,在我所稱的各業務中的「推廣壓力點」上加碼。這是必要的。美國在本季與年初至今的強勁表現令人鼓舞,但未必能確定未來是否能在那樣的水準上持續,正如 Jean-Luc Batel 上週在投資人會議中所提到的。
Clearly, emerging developing markets continues to be a priority, these are markets that are still commanding a significant piece of our incremental investment, both in infrastructure, frankly, but also promotional focus, and I think these our markets that we have to do better in. And I think we will do better going forward. But, no, don't assume that because of the challenging macro environment in Western Europe that we're abdicating that or giving up on that in any way. It continues to be, as you know, a big piece of our business and, as I said, I think there continue to be opportunities to invest in those markets as well.
顯然,新興發展中市場仍是優先事項;這些市場仍占我們增量投資的相當大一部分,坦白說包括基礎建設,也包括推廣重點,而我認為這些市場我們必須做得更好。我也認為未來我們會做得更好。但不,別因為西歐宏觀環境具挑戰性就假設我們會放棄或在任何程度上退出那裡。如你所知,西歐仍是我們業務的重要部分,而且如我所說,我認為在那些市場同樣仍有投資機會。
- Analyst
- Analyst
That's helpful. And then just one more on cash flow, Bob, this $3 billion cash flow this year, you've talked a little in the past about headwinds affecting the income statement. That $3 billion, that, I think, still includes some Colleague-related costs. How should we think about that going forward?
這很有幫助。另外再問一個關於現金流的問題,Bob,今年 30 億美元的現金流,你們過去談過一些影響損益表的逆風。這 30 億美元我想仍包含一些與 Colleague 相關的成本。我們應該如何看待未來的情況?
- Corporate VP and CFO
- Corporate VP and CFO
Yes. We've incurred more than $200 million each of the last two years. So I think if you adjust for Colleague it would be north of $3.2 billion that we would be shooting for here in 2012, and certainly we won't have that headwind going into 2013. So cash flow from operations growth, as we talked about in the investor conference last week, should be roughly in line with earnings growth so you should think about growing it off of a slightly higher base than the $3 billion that we are projecting this year.
是的。過去兩年我們每年都發生超過 2 億美元。所以我認為如果把 Colleague 調整掉,2012 年我們的目標應該會在 32 億美元以上,而且 2013 年當然不會再有這個逆風。因此,正如我們上週在投資人會議中談到的,營運活動現金流的成長應大致與盈餘成長一致,所以你可以把它視為在略高於我們今年預估 30 億美元的基礎上成長。
- Analyst
- Analyst
Okay. That's helpful. Thank you very much.
好的。這很有幫助。非常感謝。
- Corporate VP, IR
- Corporate VP, IR
Thanks, David.
謝謝你,David。
Operator
Operator
David Lewis of Morgan Stanley is on line with a question. Please go ahead with your question.
Morgan Stanley 的 David Lewis 在線上提問。請提出您的問題。
- Analyst
- Analyst
Good morning.
早安。
- Corporate VP and CFO
- Corporate VP and CFO
Good morning, David.
早安,David。
- Analyst
- Analyst
Morning, Bob. Two quick ones here. I guess the first thing is for Bob Hombach, just looking at the P&L, the gross margins this quarter were obviously very strong, but I guess they're actually the strongest they've been in three years. So maybe help us understand, Bob, the underlying factors that are kind of driving you back to where you were three years ago and sort of how sustainable you see those trend heading into next year?
早安,Bob。我這裡有兩個簡短問題。第一個是給 Bob Hombach:看損益表,本季毛利率顯然非常強勁,但我想其實是三年來最高。所以也許請你協助我們理解,Bob,是哪些基本因素讓你們回到三年前的水準,以及你認為這些趨勢在進入明年時的可持續性如何?
- Corporate VP and CFO
- Corporate VP and CFO
Certainly. Some elements, I think, are sustainable, some, I think, were specific to the third quarter. The sustainable piece is strong US demand in our hemophilia business, both for recombinant factor VIII for ADVATE, but also for FEIBA, which is one of our higher margin plasma-derived proteins. And so FEIBA growth in the US was strong as well. And we think given the focus that we have both on the ADVATE prophylaxis label and PK dosing, but also as Ludwig Hantson mentioned last week, we're very excited about the opportunities that FEIBA prophylaxis could present for us, as well. So I think those dynamics continue.
當然可以。有些因素我認為是可持續的,有些我認為是第三季特有的。可持續的部分是我們血友病業務在美國需求強勁,包含重組第八凝血因子 ADVATE,也包含 FEIBA(這是我們毛利率較高的血漿來源蛋白之一)。因此 FEIBA 在美國的成長也很強。而且我們認為,鑑於我們同時聚焦於 ADVATE 的預防性治療適應症標示與 PK 劑量調整,另外如 Ludwig Hantson 上週提到的,我們也對 FEIBA 預防性治療可能帶來的機會感到非常興奮。所以我認為這些動能會持續。
The thing that also impacted the third quarter positively for us really is a dynamic related to FX. So, as you know, Europe is one of our larger markets and certainly our euro sales are pretty substantial. So the fact that the euro was pretty weak, particularly through much of the third quarter, depressed at the sales line, but as you know, we are largely hedged, either naturally hedged or financially hedged, as it relates to the euro so we were able to preserve the margin dollars even though the reported sales number comes down. So the margin calculation itself is actually benefited as a result of that. We saw a pretty significant dynamic there. Now just within the last several weeks, you've seen the euro go from the low $1.20s up to $1.30, so we don't expect that margin FX benefit in the fourth quarter like we saw it in the third quarter, and it was more than 50 basis points in the quarter from an impact standpoint. We will see some of the that in the fourth quarter, but not anything quite that substantial. So I think those two factors, strength in US hemophilia and the FX dynamic, particularly around the euro, are what drove this significant margin,.
另外一個在第三季對我們帶來正面影響的因素,其實是與外匯(FX)相關的動態。如你所知,歐洲是我們較大的市場之一,我們以歐元計價的銷售也相當可觀。因此歐元在第三季大部分時間相當疲弱,壓低了銷售端的數字;但如你所知,就歐元而言我們大多已進行避險,不論是自然避險或金融避險,因此即使報表上的銷售數字下降,我們仍能保住毛利金額。所以毛利率的計算本身反而因此受益。我們看到相當顯著的影響。不過就在最近幾週,你已看到歐元從 1.20 美元出頭回升到 1.30 美元,因此我們預期第四季不會像第三季那樣有外匯帶來的毛利率利益;就影響幅度而言,第三季超過 50 個基點。第四季我們仍會看到其中一部分,但不會有那麼顯著。所以我認為這兩個因素——美國血友病業務的強勁,以及外匯動態、特別是歐元——推動了這次顯著的毛利率表現。
- Analyst
- Analyst
Great, that's very helpful. And then I know you've got questions, you talked about the Brazil PD factor VIII business, but if you think about the European antibody business this quarter, it was down more sharply than we would expect. And, I guess, you talked a little about tenders, I believe, in the release, but help us understand how much of that is tenders, how much of that could be impending austerity which we had not seen in the past, and how much of that is just prioritization of global pricing if you have stronger demand in US or other regions?
很好,這非常有幫助。接著我知道你們也有問題,你提到巴西的 PD 第八凝血因子(factor VIII)業務,但如果你回頭看本季歐洲的抗體業務,跌幅比我們預期更大。而且,我想你在新聞稿裡也稍微談到招標(tenders),但請幫我們理解:其中有多少是招標因素、有多少可能是我們過去未曾看到的即將到來的撙節(austerity),以及有多少只是因為若美國或其他地區需求更強,你們就優先考量全球定價的配置?
- Chairman, CEO
- Chairman, CEO
I don't think it's an austerity effect --
我不認為這是撙節效應——
- Corporate VP and CFO
- Corporate VP and CFO
No, David, it's almost entirely the latter that you just mentioned. As we've talked about, we are constrained on a global basis and trying optimize the limited supply that we have, recognizing that some of our competitors, like Octapharma, have historically had more strength in Europe and have wanted to participate in more price sensitive markets. So we've been actively shifting volume from Europe to the US, as I mentioned, starting in the second quarter, but really reaching a peak here in the third quarter and reaching what I think will be largely a run rate as we go forward here. So that really, I think, is the dynamic. There's nothing else significant going on that I am aware of. We continue to participate in markets where we think it makes sense to in Western Europe where we have a long-established position, and we think an appropriate price point, and that will be something we will support going forward. So I think we've largely done the shifts that we are going to do.
不,David,幾乎完全是你剛提到的後者。如同我們一直在談的,我們在全球範圍內供應受限,正試圖在有限供應下做最佳化配置,同時也認知到我們的一些競爭對手(例如 Octapharma)在歐洲歷來更具優勢,並且希望參與對價格更敏感的市場。因此我們一直在積極把量從歐洲移往美國,如我提到的,從第二季開始,但在第三季真正達到高峰,並且我認為接下來大致會形成一個持續的常態水準(run rate)。所以我認為這就是主要的動態。就我所知,沒有其他重大因素在發生。我們仍會在西歐那些我們認為合理、且我們長期建立地位並擁有適當價格點的市場中參與競爭,而這也會是我們未來會持續支持的方向。所以我認為我們大致已完成我們要做的轉移。
- Analyst
- Analyst
Okay. That was a deliberate Baxter strategy, not [end] market?
好的。那是 Baxter 有意為之的策略,而不是(終端)市場造成的?
- Corporate VP and CFO
- Corporate VP and CFO
Absolutely.
絕對是。
- Analyst
- Analyst
Great. Thank you very much.
很好。非常感謝。
- Corporate VP, IR
- Corporate VP, IR
Thanks, David.
謝謝你,David。
Operator
Operator
Matt Miksic of Piper Jaffray is on the line with a question. Please go ahead with your question.
Piper Jaffray 的 Matt Miksic 在線上有問題。請提出你的問題。
- Analyst
- Analyst
Thanks for taking our questions. So one follow-up here on BioScience. You've upped your expectations for recombinants in IVIG. On the recombinants, Bob, you mentioned, I think you through in this competitive conversions comment, I would love to hear you elaborate on that in addition to conversion to prophy? And on the IVIG side, I guess, I would just say help us understand how you are driving some above, I guess, better than expected growth, improving growth there against the backdrop of the manufacturing constraints and facilities maintenance you talked about? And then I have one follow-up.
謝謝讓我們提問。我這裡有一個關於 BioScience 的追問。你們上調了對 IVIG 中重組產品(recombinants)的預期。在重組產品方面,Bob,你提到我想是在談到競品轉換(competitive conversions)時順帶提到的,我很希望你能就此多做說明,除了轉換到預防性治療(prophy)之外?另外在 IVIG 方面,我想請你們幫我們理解:在你們提到的製造限制與廠房維護背景下,你們是如何推動某些、我想是超出預期的成長、並改善那邊的成長?然後我還有一個追問。
- Chairman, CEO
- Chairman, CEO
Sure. Bob, why don't you handle this?
當然。Bob,你來回答這個好嗎?
- Corporate VP and CFO
- Corporate VP and CFO
Sure. On the conversion front, I think as Ludwig highlighted last week, we had a two-prong strategy when we got the label expansion in December of last year. The first was immediately to focus on the improvement in outcomes for patients in reducing bleeds to on average less than one, but overall for up to 40% of the patients or more no bleeds at all. So we started immediately with that and started to see some conversion from competitive products even in the beginning of this year. And now with the opportunity to more actively market the PK dosing for every three-day dosing we continue to be confident we're going to have opportunities there to be very competitive and potentially take some additional share as we go forward. So we're very familiar with this community, we literally know it patient by patient, so we have very good tracking mechanisms to understand as patients come on to prophy are they switching from on-demand, from a Baxter product or on-demand from a competitor product or competitive prophy to prophy. So we've got reasonably good visibility there.
好的。在轉換(conversion)方面,我想如同 Ludwig 上週強調的,我們在去年 12 月取得適應症標籤擴增(label expansion)後,採取了雙軌策略。第一是立刻聚焦於改善病患結果,把出血事件(bleeds)降低到平均少於一次;而整體而言,最多可讓 40% 或更多的病患完全不出血。所以我們立刻從這點著手,並在今年一開始就看到一些從競品轉換過來的情況。而現在,隨著我們能更積極行銷每三天一次的 PK 劑量(PK dosing)方案,我們仍有信心能在那裡取得機會、具備很強競爭力,並在未來可能再拿到一些額外市占。我們非常熟悉這個社群,幾乎是逐一病患地了解,因此我們有非常好的追蹤機制,能掌握病患開始採用預防性治療(prophy)時,是從按需治療(on-demand)轉換而來(不論是 Baxter 產品或競品),或是從競品的預防性治療轉到我們的預防性治療。所以我們在這方面有相當不錯的能見度。
On the IG front, it's a combination of two things, Matt. One is we're running at very, very low levels of safety stock, uncomfortably low, I would say, but the demand has been so strong we're doing everything we can to meet market demand and so that has put us in a situation of being on back order on a pretty consistent basis. So we've maybe stretched the volume side of this a bit here in 2012 from our original expectation, but the demand has been so strong. But also this dynamic, as we mentioned in the prepared comments, and as I just mentioned to -- on the other question, the shift from Europe to the US, there is a fairly meaningful price differential from 20% to 30% in some cases and so that provides some benefit to the sales line from a mix perspective, as well. So it's a combination of really doing everything we can on the volume side and giving (inaudible) mix benefit as well, along with the very modest price increase that we talked about previously that we took in US.
在 IG 方面,Matt,這是兩個因素的組合。第一,我們的安全庫存(safety stock)水位非常、非常低,我會說低到令人不安;但需求非常強勁,我們正盡一切努力滿足市場需求,因此我們幾乎持續處於缺貨待補(back order)的狀態。所以在 2012 年,我們在出貨量(volume)面可能比原先預期多拉了一些,但需求確實非常強。第二,如同我們在事先準備的評論中提到、以及我剛才在另一個問題中提到的,從歐洲轉向美國的配置,某些情況下存在 20% 到 30% 的顯著價差,因此從產品組合(mix)角度也會對營收(sales line)帶來一些助益。所以這是我們在量的面向上盡最大努力、同時也帶來(聽不清)組合效益,再加上我們先前提到在美國採取的非常溫和的價格上調。
- Chairman, CEO
- Chairman, CEO
Just to loop back on the recombinant question, I think it's fair to say that the volume strength is primarily attributed to the uptake really on prophylaxis, which is different than a share shift dynamic. The clinical data on the low bleed rate has been very effective in a competitive context, but I think the prophylaxis label has really been the primary driver in the strength to date. And as Mary Kay commented in one of the earlier questions, we are still in the early stages of, I think, penetrating the opportunity that exists here. So as we commented, we are quite encouraged about that.
回到重組產品的問題,我想可以公平地說,量的強勁主要歸因於預防性治療的採用提升(uptake),這與市占轉移(share shift)的動態不同。低出血率的臨床數據在競爭情境下非常有效,但我認為迄今為止,預防性治療的標籤(prophylaxis label)才是帶動強勁表現的主要驅動因素。而且如同 Mary Kay 在先前某個問題中提到的,我們仍處於、我認為、滲透這個機會的早期階段。因此如我們所說,我們對此相當受到鼓舞。
- Analyst
- Analyst
Very helpful. And then the follow-up on Brazil, you talked about a predominantly FEIBA impact in the quarter, tender related impact. If you could maybe, it would be helpful to frame out sort of the bigger picture of the opportunity in Brazil. You talked a lot, Bob, last week about the strategic public-private partnership there, it's still pending, but is there an opportunity for these two -- do you have an opportunity to do something across hemophilia broadly that would include FEIBA and PD and ADVATE, or should we think about these tender and partnership opportunities along sort of therapies and product lines?
非常有幫助。接著追問巴西,你提到本季主要是 FEIBA 的影響、且與招標相關。如果可以的話,或許請你們協助勾勒巴西機會的更大圖像會很有幫助。Bob,你上週談了很多那邊的策略性公私合營夥伴關係(public-private partnership),目前仍在等待中,但這兩者是否存在機會——你們是否有機會在更廣泛的血友病(hemophilia)領域做一些事情,涵蓋 FEIBA、PD 與 ADVATE?還是我們應該把這些招標與合作夥伴機會視為沿著不同療法與產品線分別推進?
- Chairman, CEO
- Chairman, CEO
Well, again, I am somewhat limited until we finalize the agreement. And as I commented at the conference last week, really the only reason that I even commented on this is there has been a local publication on the award that was given, the exclusive award that was given to Baxter, and given that it is in the public domain I did want to comment on it. The fact that the contract is not finalized, I think, we're somewhat limited to offer too many more specifics, Matt, than what we shared last week. But just to reiterate a few things that we did comment on last week, just so if there's some callers this morning that didn't follow that. It is an exclusive award, specifically as it relates to recombinant factor VIII, okay. We think the opportunity is significant, we commented Brazil is the third largest hemophilia market in the world with more than, I think it's about 10,000 individuals, is that right, Mary Kay, that have hemophilia A in Brazil?
嗯,再次說明,在我們完成協議之前,我能談的內容有些限制。而且如我上週在會議上所說,我之所以會提到這件事,唯一原因是當地有出版物報導了這項授予 Baxter 的得標——授予 Baxter 的獨家授標(exclusive award);既然已屬公開資訊,我確實想對此做些評論。但由於合約尚未定案,我想我們在提供比上週分享內容更多的細節方面會有所限制,Matt。不過我再重申幾點我們上週提到的內容,讓今天早上可能沒有追到那場會議的聽眾也能了解。這是一項獨家授標,特別是針對重組第八凝血因子(recombinant factor VIII),好嗎。我們認為機會相當可觀;我們提到巴西是全球第三大血友病市場,患者超過——我想大約是 10,000 人,對嗎,Mary Kay?在巴西罹患 A 型血友病(hemophilia A)的人數?
The intent of the Brazilian government, and this is one of the largest plasma-derived markets in the world, is to, in as short order as possible, fundamentally convert all those plasma-derived patients to recombinant. So this is a material opportunity and given the exclusive nature of it clearly puts us in a position where we're able to establish, I think, the relationship with both the treaters and the patients that should benefit us on other hemophilia-related products over time that are not part and parcel to the specific collaboration. So you mentioned FEIBA, that would be an example, but certainly future products like factor VII, factor IX, von Willebrand's, longer acting and so on are not really part of the agreement but would allow us to build on this foundation going forward.
巴西政府的意圖——而這也是全球最大的血漿衍生製劑市場之一——是要在盡可能短的時間內,從根本上將所有使用血漿衍生製劑的患者轉換為重組製劑。因此,這是一個重大的機會;而且鑑於其排他性,顯然使我們處於一個能夠建立——我認為——與治療端及患者之間關係的位置,這些關係將隨時間推移在其他與血友病相關、但並非該特定合作協議一部分的產品上讓我們受益。所以你提到 FEIBA,那會是一個例子;但當然,未來像第 VII 因子、第 IX 因子、von Willebrand 氏病相關產品、更長效的產品等等,並不真正屬於協議的一部分,但將使我們能在此基礎上持續向前發展。
So at this point, I think I am going to stop so I won't share any more than I should, but like I say when the contract gets finalized, which hopefully will be in the next -- within the next several weeks, then we will be very specific. But I think you can conclude this is a material opportunity, and as I commented last week it is a model, an example of what I referred to as public-private partnerships, this fourth vector for growth of government collaborations, and I think it can be an example of some things that we're going to try to do elsewhere. In fact, as I commented last week, we actually have active discussions on other businesses with other countries. So stay tuned on that.
所以在這個時間點,我想我會先停在這裡,避免分享超出我應該透露的內容;但如我所說,當合約最終定案時——希望會在接下來幾週內——我們就會非常具體。但我想你可以得出結論:這是一個重大的機會;而且如我上週評論的,這是一個模式、也是我所稱之為公私協力(public-private partnerships)的例子,是政府合作這第四個成長向量,我認為它也可以成為我們在其他地方嘗試推動的一些事情的範例。事實上,如我上週所說,我們確實正在就其他業務與其他國家進行積極討論。所以請持續關注。
- Analyst
- Analyst
Thanks.
謝謝。
- Corporate VP, IR
- Corporate VP, IR
Thanks, Matt. Next question, Sean?
謝謝你,Matt。下一個問題,Sean?
Operator
Operator
Thank you. Mike Weinstein of JPMorgan is on the line with a question. Please go ahead with your question.
謝謝。摩根大通(JPMorgan)的 Mike Weinstein 在線上有問題。請提出您的問題。
- Analyst
- Analyst
Thanks, first off I apologize, I was caught between two calls at the same time earlier so --
謝謝,首先我道歉,我先前同時卡在兩通電話之間,所以——
- Chairman, CEO
- Chairman, CEO
I'm impressed at how quickly you got back in the queue, Mike. (laughter)
Mike,你這麼快就回到提問隊列,我很佩服。(笑聲)
- Analyst
- Analyst
Well, I actually got back faster, just finally --
嗯,其實我回來得更快,只是終於——
- Chairman, CEO
- Chairman, CEO
Go ahead.
請繼續。
- Analyst
- Analyst
Well, thanks. I really don't have that much on the quarter. I do, Bob, want to spend a minute on just M&A strategy, particularly in the medication delivery side of the business. Could you just talk a little bit about how you think, you commented on this in a couple of ways at the analyst meeting, but could you just comment a little bit about how you think leveraging certain assets in the med delivery portfolio going forward, if the goal is you've got certain strengths, whether it's manufacturing certain types of products, delivery within the hospital, we could go on. How do you think about building that business through M&A over the next three to five years?
好的,謝謝。我對本季其實沒有太多問題。不過,Bob,我想花一分鐘談談併購(M&A)策略,特別是在業務的藥物輸送(medication delivery)端。你能否稍微談談你對於未來如何運用藥物輸送產品組合中的某些資產的看法?你在分析師會議上以幾種方式提到過,但能否再多評論一下:如果目標是你們具備某些優勢——不論是製造某些類型的產品、在醫院內的配送,我們還可以列舉更多——你如何看待在未來三到五年透過併購來打造這項業務?
- Chairman, CEO
- Chairman, CEO
I would just say, I think the Baxa deal that we did earlier in the year probably is a good example of the kinds of things we're going to continue to look at. It's about -- we talk about adjacencies, bolt-ons, we use a lot of terms like that, but any deals that we do have to have what I call, I've coined the term no kidding around synergies. When you do acquisitions it's easy to position them as strategically compelling and all these words that get thrown around, but there have to be legitimate synergies. The Baxa deal clearly leveraged our channel in relationship with the hospital pharmacy. It became an extension of our strength with pre-mixes to expand in formulated products within the hospital pharmacy. And so whether it's channel, whether it's technology, when you do deals you have to be convinced that one plus one is greater than two. And so I think in many ways the Baxa deal, as I said, incorporates a number of the characteristics of the kinds of deals with Medical Products that we're going to continue to target. As I commented last week, I don't see us doing deals really outside of the framework of the businesses that we're in today.
我只能說,我認為我們今年稍早完成的 Baxa 交易,可能就是我們將持續關注的那類事情的一個很好的例子。這關乎——我們會談到相鄰領域(adjacencies)、補強型併購(bolt-ons),我們用了很多這類術語——但我們做的任何交易都必須具備我所稱、我自己創造的一個詞:不是開玩笑的協同效益(no kidding around synergies)。做併購時,很容易把它包裝成「戰略上很有吸引力」以及各種被反覆使用的詞,但必須要有真正的協同效益。Baxa 交易顯然運用了我們在醫院藥局通路上的關係。它成為我們在預混(pre-mixes)方面優勢的延伸,讓我們在醫院藥局內的配方產品(formulated products)上得以擴張。因此,不論是通路、或是技術,做交易時你必須確信一加一大於二。所以我認為在很多方面,正如我所說,Baxa 交易包含了我們將持續鎖定的醫療產品(Medical Products)類交易的多項特徵。如我上週評論的,我不認為我們會在目前所處的業務框架之外去做交易。
In other words, fundamentally new areas of healthcare, because I think there's enough opportunities in business development and acquisitions to leverage strengths that we have in our core businesses. And that includes BioScience, not just in Medical Products. That's where we want to focus, that's where the value really gets created and the risk gets managed, and there's always risk when you do acquisitions but that's one of the ways you create a buffer for any risk that is encountered is that there is a compelling synergy that is deliverable. So I'll stop there, I don't know, Bob, or Mary Kay, if you want to add to that? Does that answer your question, Mike, is that helpful?
換句話說,不會進入全新的醫療保健領域,因為我認為在業務發展與併購方面,有足夠多的機會可以運用我們在核心業務上的優勢。這也包括 BioScience,不僅僅是 Medical Products。那是我們想要聚焦的地方;價值真正被創造、風險也被管理的地方。當然做併購總是有風險,但你用來為可能遇到的風險建立緩衝的一種方式,就是確保存在可交付的、具說服力的協同效益。所以我先說到這裡。我不知道 Bob 或 Mary Kay 是否想補充?Mike,這有回答你的問題嗎?有幫助嗎?
- Analyst
- Analyst
Yes, I think it does. There's been some additional commentary in the press in the last 24 hours, as well, talking about potential targets for you guys. So let me switch gears, though. On pipeline news over the next few months, could you just talk a little bit about how you think you'll update the Street, number one, on your HyQ discussions with the FDA? As you gain greater clarity there on the preclinical path, will that just come on the fourth quarter call? And then second, just to be clear on your thoughts on how you'll disclose on Alzheimer's?
是的,我想有。另外,過去 24 小時媒體上也有一些額外評論,談到你們可能的併購標的。不過我先換個話題。關於未來幾個月的研發管線消息,你能否稍微談談你們打算如何向市場更新:第一,關於你們與 FDA 就 HyQ 的討論?當你們對前臨床路徑有更清楚的掌握時,是否會等到第四季電話會議才說?第二,為了釐清,你們打算如何揭露阿茲海默症相關資訊?
- Chairman, CEO
- Chairman, CEO
I'm not sure we're going to have anything on that before the fourth quarter call in January. Norbert -- this is Dr. Riedel, Mike. Norbert, why don't you maybe address this and then Bob, or Mary Kay --
我不確定在一月的第四季電話會議之前,我們是否會有任何可分享的內容。Norbert——我是 Riedel 醫師,Mike。Norbert,你要不要先回應一下,然後 Bob 或 Mary Kay——
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
So, Mike, we touched on it last week at the conference. On the HyQ, we are still planning to request a meeting with the agency by year end to discuss what we have done in the area of additional preclinical data, what else they are looking for. Until we have had that meeting and discussion, it will be difficult to predict when we will resubmit and actually move towards a review. On other news that you should be expecting this year --
所以,Mike,我們上週在會議上有提到。關於 HyQ,我們仍計畫在年底前向主管機關申請會議,討論我們在補充前臨床數據方面已完成的工作,以及他們還希望看到什麼。在我們完成那次會議與討論之前,很難預測我們何時會重新遞交(resubmit),並實際推進到審查(review)。至於你今年還應該期待的其他消息——
- Analyst
- Analyst
By the way, Norbert, I was talking about after you have had that meeting, what type of disclosure we would expect, whether that we just wait for the 4Q call?
順帶一提,Norbert,我指的是在你們開完那個會之後,我們預期會以什麼樣的方式對外揭露;是否就等到第四季電話會議?
- Corporate VP, IR
- Corporate VP, IR
I think, Mike, it will depend on the timing and what opportunities we have to communicate and what type of information we have to communicate. So I don't know that we have an answer today for your question.
我想,Mike,這將取決於時點,以及我們有哪些溝通機會、以及我們有哪些資訊可以溝通。所以我不確定今天我們能對你的問題給出答案。
- Analyst
- Analyst
Understood.
了解。
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
And on the hemophilia pipeline, I think as we move forward with our BAX 855, our longer-acting factor VIII, we plan to have an IND submitted by year end, as we mentioned, and we will report out on the Phase I data. Typically, although we haven't done final decisions, typically large symposia, like the hemophilia meeting, would be a forum where we'd talk about this data, and so it will be within the format of what we typically do. On VII A, the same, we will go into the Phase III by year end and make those announcements as we actually get the okay from the regulators to proceed.
至於血友病研發管線,我想隨著我們推進 BAX 855——我們的長效型第 VIII 因子——我們計畫如先前所提,在年底前提交 IND,並且我們會公布第一期(Phase I)數據。通常——雖然我們尚未做出最終決定——通常大型研討會,例如血友病會議,會是我們討論這些數據的場合;因此會以我們一貫的方式來進行。至於 VII A 也是一樣,我們將在年底前進入第三期(Phase III),並在我們實際取得監管機關同意推進後,發布相關公告。
- Corporate VP, IR
- Corporate VP, IR
Mike, and I would add on Alzheimer's, I think it's similar to the HyQ situation. It will depend on what type of information, the timing of the information and what we have to disclose. So we've made no decisions at this point.
Mike,另外我也想補充一下阿茲海默症,我認為這和 HyQ 的情況類似。這將取決於資訊的類型、資訊的時點,以及我們必須揭露哪些內容。因此,我們目前尚未做出任何決定。
- Analyst
- Analyst
Okay. Thank you, guys.
好的。謝謝各位。
- Chairman, CEO
- Chairman, CEO
Okay, Mike, thanks.
好的,Mike,謝謝。
- Corporate VP, IR
- Corporate VP, IR
Next question, Sean?
下一題,Sean?
Operator
Operator
Jonathan Palmer of CLSA is on the line with a question. Please go ahead with your question.
CLSA 的 Jonathan Palmer 在線上提問。請提出您的問題。
- Analyst
- Analyst
Good morning, and thanks for taking the question.
早安,謝謝讓我提問。
- Chairman, CEO
- Chairman, CEO
Sure, Jonathan, go ahead.
當然,Jonathan,請說。
- Analyst
- Analyst
For Bob Parkinson, I just wanted to follow-up on a strategic topic from last week's meeting, and you touched a little bit on this with Matt's question. One of the growth vectors you discussed last week was this public and private partnerships and we spent a little more time on the Brazilian recombinant deal this morning. My question for you is, how you institutionalize this objective across the organization and really leverage the portfolio, and is there a formal group responsible for pushing this initiative?
想請教 Bob Parkinson,我想延續上週會議中一個策略性議題,你在回答 Matt 的問題時也稍微提到。你們上週談到的成長向量之一是公私部門夥伴關係,而今天早上我們也花了更多時間討論巴西的重組產品交易。我的問題是,你們如何在整個組織內制度化這個目標、真正槓桿運用產品組合?是否有一個正式的團隊負責推動這項倡議?
- Chairman, CEO
- Chairman, CEO
Yes, that's a great question, Jonathan. Well, one of the areas that we've really focused on this year is broadening our engagement and really the global resources, focused on what we call market access which is beyond the traditional go-to-market model of feeling the sales force and detailing the health care professionals. We've always had gap organizations in place that have established relationships with the government. But locally in the country but roll up to the regions, as well as in the US, we've increasingly, I think, formalized the process that we are becoming increasingly in tune to what the priorities are of the governments who, at the end of the day, are the players for most of healthcare. And then identifying those areas in which we think we can be a viable partner. As an example, and I won't say which government it is, but we had representatives from the Health Ministry here in Deerfield a couple of weeks ago talking about several different issues of priority for them, one of which is a common theme almost around the world that governments are challenged by is how do they manage the escalating cost of treating end-stage renal disease.
是的,Jonathan,這是個很好的問題。我們今年真正聚焦的一個領域,是擴大我們的參與度以及全球資源,重點放在我們所稱的「市場准入」,這超越了傳統的上市推廣模式,也就是配置銷售團隊並向醫療專業人員進行產品說明。我們一直都有相關組織,建立與政府的既有關係。但在各國當地、並向各區域彙報,以及在美國,我認為我們已愈來愈把流程正式化,讓我們更能掌握政府的優先事項;畢竟到最後,政府在多數醫療體系中都是關鍵角色。接著辨識我們認為可以成為可行合作夥伴的領域。舉例來說(我不會說是哪個政府),幾週前有衛生部的代表來到 Deerfield,與我們討論他們優先處理的幾個不同議題,其中之一幾乎是全球共同的主題:各國政府都面臨如何管理末期腎臟病治療成本不斷攀升的挑戰。
And increasingly there is an open-mindedness and a recognition that treating patients in the home not only is more convenient for the patient, often times can lead to enhanced clinical outcomes, but clearly care can be delivered at a lower cost than the traditional in-center type of environment. So we have and we will continue to expand our resources, refine our competencies in a non-traditional way starting with attempting to understand and empathize with the position of the governments and the payers on what their priorities are and then doing a cross match with the therapies that we are in, whether it's end-stage renal disease, whether it's in plasma therapeutics, or whatever it may be, where through our leadership position we believe objectively we present ourselves as a viable partner and challenge them to open their minds to a different way of collaboration. One of the things that I feel very strongly about is I think, I used this expression last week, necessity is the mother of invention, and I think the need is becoming so intense for governments and payers it is forcing them to say we have to think about unconventional and different ways to partner with industry if we are fundamentally going to get of these cost drivers that historically everyone has been frustrated with their inability to deal with. And the traditional vendor-customer relationship where price on the product is the only variable, clearly we understand why people are focused on that to try to attempt to drive cost down but we're reaching floors in that. And so we're really perceiving in developed markets an open-mindedness to collaborate in ways that heretofore they haven't.
而且大家愈來愈開放,也逐漸認知到,讓病人在家中接受治療不僅對病人更方便,往往也能帶來更好的臨床結果,而且很明顯地,照護成本可以低於傳統的院內(中心)治療環境。因此,我們已經、也將持續擴充資源,以非傳統方式精進我們的能力;從嘗試理解並同理政府與支付方的立場、了解他們的優先事項開始,然後再與我們所涉入的治療領域進行對照,不論是末期腎臟病、血漿治療,或其他領域;在這些領域中,憑藉我們的領導地位,我們客觀上相信自己能成為可行的合作夥伴,並促使他們以不同方式思考合作。我非常強烈地認為——我上週也用過這句話——「需求是發明之母」。我認為政府與支付方的需求正變得非常迫切,迫使他們說:如果我們要從根本上處理這些歷來讓所有人都挫折、卻難以應對的成本驅動因素,就必須思考與產業合作的非常規、不同方式。傳統的供應商—客戶關係中,產品價格是唯一變數;我們當然理解為何大家會聚焦在這點以試圖壓低成本,但我們已經接近其下限。因此,在已開發市場,我們確實感受到一種更開放的態度,願意以過去未曾有過的方式進行合作。
Conversely, in emerging markets who have the challenge of providing access at what we call the base of the pyramid, which is as much of their population as possible to therapies, they too are looking for ways to finance access more broadly to care. And, again, the traditional, what I call Western models of go-to-market, I think, have to be challenged and turned on end as it relates to emerging markets. So I'll stop there, I touched on several different elements but there is a reason we broke this out as a fourth growth vector. We used the examples of the recent Sanguin collaboration. Jean-Luc took the group last week through the collaboration on what's referred to as the PD First program in Thailand. We hope to share more specifics with you shortly on the collaboration in Brazil. But I think these are just the first of what is now going to be a continuing stream over time of collaborations that are going to be significant triggers to our growth.
相對地,在新興市場,他們面臨的是在我們所稱的「金字塔底層」提供可近性(也就是讓盡可能多的人口能取得治療)的挑戰,他們同樣在尋找更廣泛為照護可近性提供資金的方式。而且,我認為傳統的、我所稱的西方上市推廣模式,在新興市場必須被挑戰並徹底翻轉。我先說到這裡;我提到了幾個不同面向,但這也是我們把它列為第四個成長向量的原因。我們也舉了近期與 Sanguin 合作的例子。Jean-Luc 上週向大家介紹了在泰國所謂的「PD First」計畫合作。我們希望很快能與各位分享更多關於巴西合作的具體細節。但我認為,這些只是第一步;未來一段時間,這將成為持續不斷的合作串流,而這些合作將成為推動我們成長的重要觸發因素。
- Analyst
- Analyst
That was very helpful. I'll just leave it at one. Thank you.
這非常有幫助。我就先問這一題。謝謝。
- Corporate VP, IR
- Corporate VP, IR
Thanks, Jonathan.
謝謝你,Jonathan。
- Chairman, CEO
- Chairman, CEO
Thank you, Jonathan
謝謝你,Jonathan。
- Corporate VP, IR
- Corporate VP, IR
We have time for two more questions, Sean.
Sean,我們還有時間再問兩題。
Operator
Operator
Okay, our next question comes from Matt Taylor of Barclays. Please go ahead with your question.
好的,下一題來自 Barclays 的 Matt Taylor。請提出您的問題。
- Analyst
- Analyst
Hi, thanks for taking the question.
嗨,謝謝讓我提問。
- Chairman, CEO
- Chairman, CEO
Sure, Matt.
當然,Matt。
- Analyst
- Analyst
How are you guys? I just had a question on prophy, clearly that's been a great driver for you in recombinants. I wanted to understand in terms of units, when patients convert from on-demand to prophy how much of a benefit is that for you in terms of total volume?
你們好嗎?我想問一下預防性治療(prophy),很明顯這一直是你們重組產品的一個重要驅動因素。我想了解就用量(units)而言,當病人從按需治療(on-demand)轉為預防性治療時,對你們的總用量帶來多大的好處(提升)?
- Chairman, CEO
- Chairman, CEO
It significant, Mary Kay?
這很顯著,Mary Kay?
- Corporate VP, IR
- Corporate VP, IR
Yes, moving from on-demand therapy, which could be 44 bleeds a year, to prophylaxis where you are taking it, depending on whether you are doing it PK or through standard prophylaxis, either two times or three times a week. You are probably talking volume increase of about 2 to 3 times the volume.
是的,從按需治療(可能一年出血 44 次)轉為預防性治療;預防性治療則視你是採 PK(藥物動力學)導向或標準預防方案而定,通常是一週兩次或三次。你談到的用量增加,大概是增加到原來的 2 到 3 倍。
- Analyst
- Analyst
Okay. Great. I have read papers that say it's from 2 to 6 times, so 2 to 3 is helpful.
好的。很好。我讀過一些論文說是 2 到 6 倍,所以 2 到 3 倍這個說法很有幫助。
- Corporate VP, IR
- Corporate VP, IR
You know this is a weight -based. I wouldn't say 6 sounds a little high, Matt, but it is weight-based so it does depend. It is customized to the patient.
你知道,這是以體重為基礎的。我不會說 6 倍——聽起來有點高,Matt——但確實是依體重計算,所以會有所不同。這是為病人量身訂做的。
- Analyst
- Analyst
Okay, great. Appreciate it. A difficult market, you guys delivered a decent quarter here, and you talked last week about your long-range plan goals. The growth here was a little bit lower than your goals and I know you said that it's going to be backend loaded. Can you help us with sort of the shape of the curve there over the five years in terms of how you think the growth is going to be this year and next year and in the out years?
好的,很好。感謝。在一個艱難的市場環境下,你們這一季交出不錯的成績;而你們上週也談到長期計畫的目標。這裡的成長略低於你們的目標,我知道你們說會是後段發力。你能否協助我們理解一下,從五年期來看成長曲線大概會是什麼形狀?也就是你們認為今年、明年以及之後幾年的成長會如何分布?
- Corporate VP and CFO
- Corporate VP and CFO
Actually, Matt, what I mentioned was during the conference that it actually won't be that dramatic on either side of that approximately 5%. And the dynamics are in the outer years we will have more new products contributing to top line and bottom line growth, but we will also have increased competition, whether it's in the hemophilia space for factor VIII, or in Suprane and cyclophosphamide on the Medical Products side.
其實,Matt,我在會議上提到的是,在大約 5% 這個水準的上下兩側,實際上不會有那麼劇烈的變化。而在較後期的年度,我們會有更多新產品對營收與獲利成長做出貢獻,但同時競爭也會加劇,不論是在血友病領域的第八凝血因子(factor VIII),或是在醫療產品端的 Suprane 與 cyclophosphamide。
And in the near term, as we start ramping up capacity, particularly in 2014, that will help the plasma situation but in '13 we are still constrained. So as you think about the dynamics around the approximately 5% I don't see a big swing over the five years plus or minus around that range going forward.
而在短期內,隨著我們開始提升產能,特別是在 2014 年,這將有助於血漿供應狀況,但在 2013 年我們仍然受限。因此,當你思考大約 5% 左右的動態時,我不認為未來五年以上在該區間上下會有很大的擺動。
- Analyst
- Analyst
Okay. Great. Thank you, very helpful.
好的。很好。謝謝,非常有幫助。
- Corporate VP, IR
- Corporate VP, IR
Thanks, Matt. Our last question, Sean?
謝謝你,Matt。我們最後一個問題,Sean?
Operator
Operator
All right. Our last question, we have Glenn Novarro of RBC Capital Markets on the line. Please state your question.
好的。我們最後一個問題,線上有 RBC Capital Markets 的 Glenn Novarro。請提出你的問題。
- Analyst
- Analyst
Yes, thanks. This is Brandon on for Glenn. First, can just give us an update on what you're seeing in terms of Octapharma regaining footing in the US? Are you still seeing -- still not really seeing Octapharma in the US? And then also could you give us your expectations for US IVIG pricing as the contracts are renegotiated for 2013? Thanks.
是的,謝謝。我是代 Glenn 發問的 Brandon。首先,能否更新一下你們觀察到 Octapharma 在美國市場重新站穩腳步的情況?你們是否仍然看到——仍然不太看到 Octapharma 在美國的存在?另外,隨著 2013 年合約重新談判,你們對美國 IVIG 定價的預期為何?謝謝。
- Corporate VP and CFO
- Corporate VP and CFO
Given the strength of the demand in the US, the Octapharma return has effectively been a non-factor for Baxter given our product constraints, even though we've shifted a fair amount of product to the US to try to meet this very strong demand. They are still operating with a suboptimal offering of a 5% concentration versus the 10% everybody else has. And despite being one of the lower-priced players in the market, they really haven't, I think, had much of an impact. But, again, I think this really is about the strength of demand in the US kind of overwhelming any of these other factors. So it really hasn't hit our radar screen.
鑑於美國需求強勁,對 Baxter 而言,Octapharma 的回歸基本上不是影響因素,因為我們本身就受產品供應限制所困,儘管我們已將相當多的產品轉往美國,以試圖滿足這非常強勁的需求。他們目前仍以 5% 濃度的次佳產品供應在運作,而其他所有人都是 10%。而且儘管他們是市場上價格較低的業者之一,我認為他們其實並沒有造成太大影響。但再說一次,我認為這主要是美國需求的強度,某種程度上壓過了其他這些因素。所以這真的沒有進入我們的雷達範圍。
- Corporate VP, IR
- Corporate VP, IR
And we would not comment, Brandon, on IVIG pricing and contracts going into the contracting season.
而且 Brandon,我們不會在進入簽約季時評論 IVIG 的定價與合約。
- Corporate VP and CFO
- Corporate VP and CFO
Yes.
是的。
- Analyst
- Analyst
Okay. And also, are there any large BioScience tender that we need to be keeping an eye out for?
好的。另外,有沒有任何大型的 BioScience 標案需要我們特別留意?
- Corporate VP and CFO
- Corporate VP and CFO
Well, the one that is still pending in the recombinant space is the Canadian tender and so we have been informed that we have been awarded a portion of that tender. That's pretty consistent with our current position in the marketplace. The CBS has asked us to not be specific about the details, but I would tell you that the pricing is pretty consistent with what we see another major tender markets. And so as we go into 2013 that will be a modest headwind. But given all the other factors we talked about, the ADVATE prophy in US, the potential opportunity in Brazil, our opportunity to continue to penetrate other emerging markets like China with approval now, and eventually Russia by 2013 with ADVATE, as well, we don't think that's going to be a net headwind for the year overall for the recombinant franchise. But other than that there's no major tenders pending.
嗯,在重組(recombinant)領域仍在進行中的標案是加拿大的標案,我們已被告知我們獲得了其中一部分。這與我們目前在市場上的地位相當一致。CBS 要求我們不要具體說明細節,但我可以告訴你,價格水準與我們在其他主要標案市場看到的相當一致。因此,進入 2013 年後,這會帶來溫和的逆風。但考量我們談到的其他因素——例如 ADVATE 在美國的預防性治療(prophy)、巴西的潛在機會、我們在中國已獲核准後持續滲透其他新興市場的機會,以及到 2013 年 ADVATE 也有望進入俄羅斯——我們不認為這會在全年層面對重組產品線(recombinant franchise)造成淨逆風。除此之外,沒有其他重大標案在進行中。
- Corporate VP, IR
- Corporate VP, IR
Right. And I would say, Brandon, too, that this is the fourth and last of the national tenders that have played out over the last several years. So we will be soon approaching a time where we may be participating in these tenders when they are renewed over the next coming -- the coming years which, again, is not included in our long-range guidance.
對。另外我也想說,Brandon,這是過去幾年陸續完成的第四個、也是最後一個國家級標案。因此,我們很快將進入一個時點:在未來幾年這些標案續約時,我們可能會參與其中;而這同樣未納入我們的長期指引。
- Analyst
- Analyst
Okay. Thanks.
好的。謝謝。
- Chairman, CEO
- Chairman, CEO
Thanks, Brandon.
謝謝你,Brandon。
Operator
Operator
Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating.
各位女士、先生,Baxter International 今日的電話會議到此結束。感謝各位參與。